Allergan reported $4.3 billion in fourth quarter GAAP net revenues, a 12% increase over the previous year’s fourth quarter, according to a company press release. Full-year net revenues increased to $15.9 billion.

GAAP operating loss from continuing operations was $90.5 million in the fourth quarter and $5.9 billion for the year, which the company attributed to impairment charges and research and development costs.